BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  GSK Trial Data Shows Strong Support for Two-Drug Regimen Option For Treating HIV Patients

  GlaxoSmithKline continues to make headway in the development of two-drug regimens to benefit HIV patients – even those who have high levels of the virus.

  July 24, 2018

   · 

  3 min read

   · 

  Alex Keown
• 

  Business

  Arc Bio Launches Antimicrobial Resistance Software

  Arc Bio launched its proprietary antimicrobial resistance (AMR) software. It is the first in what it expects to be a series of next-generation sequencing (NGS)-based products for pathogen detection.

  July 24, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  AbbVie, Neurocrine Snag FDA Approval for Oral Endometriosis Treatment Elagolix

  Shares of AbbVie are up slightly this morning after the company announced that it finally received regulatory approval for its endometriosis drug elagolix. The approval marks the first new approved oral treatment for endometriosis-associated pain in more than 10 years.

  July 24, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  11 Babies Die After Pregnant Women Given Viagra During Dutch Drug Trial

  Dutch researchers have halted a clinical trial testing the use of Pfizer’s erectile dysfunction drug Viagra in women following the death of 11 babies. The drug was being used to see if it would help boost the growth of a baby while it was still in the womb.

  July 24, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Biogen Revenue Grows 9% in 2Q, Plans to Push Ahead with Alzheimer’s and Acquired New Assets

  Biogen reported strong sales for the second quarter, with total revenues of $3.4 billion, up 9 percent compared to the same period in 2017.

  July 24, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  FDA Report Raises Concerns Over Future of GSK’s Proposed COPD Treatment

  Months after GlaxoSmithKline unveiled positive long-term data that showed Nucala is an effective treatment for patients with severe asthma, a U.S. FDA staff report is casting doubts on its potential as a treatment for chronic obstructive pulmonary disease (COPD).

  July 24, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Gottlieb Is Backing Biosimilars In a Big Way. Does It Matter?

  If there’s one thing that defines the tenure of FDA Commissioner Scott Gottlieb, it is his outspoken mission to lower drug prices by introducing more competition into the biopharmaceutical market. And a big part of that mission has been doing what he can to boost the nascent biosimilar industry.

  July 24, 2018

   · 

  3 min read

   · 

  Karl Thiel
• 

  Business

  Pharma a Significant Driver for Eli Lilly’s 2Q, Company Plans IPO for Animal Health Business

  Shares of Eli Lilly jumped in premarket trading after the company reported total revenue of $6.35 billion for the second quarter, a 9 percent increase in revenue over the same period last year.

  July 24, 2018

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Merck’s Doravirine HIV Treatment Data Presented at AID Conference

  Merck presented results from Week 96 of its Phase III DRIVE-FORWARD clinical trial of doravirine in HIV. The data was presented in an abstract at the 22nd International AIDS Conference being held in Amsterdam.

  July 24, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Policy

  China Biopharma Company Risks De-Listing After Data Fraud

  Chinese biopharmaceutical company, Changsheng Bio-Technology, is under investigation by Chinese regulators for allegedly falsifying data for a number of products.

  July 24, 2018

   · 

  4 min read

   · 

  Mark Terry